Abstract:Over the past decades, nonalcoholic fatty liver disease (NAFLD) has become a common dysmetabolic syndrome globally, with increasing prevalence in Asia. 1,2 The definition of NAFLD in most guidelines regardless of region is the accumulation of excess fat in the liver that is not because of heavy alcohol use. 2–4 NAFLD can be further subclassified into nonalcoholic fatty liver and nonalcoholic steatohepatitis (NASH); the latter includes fibrosis, cirrhosis, and hepatocellular carcinoma. 4 Our present understanding of NAFLD has expanded from being a hepatic manifestation of metabolic syndrome (MetS) to promoting atherosclerotic process, eventually leading to atherosclerotic cardiovascular diseases (ASCVDs) including coronary artery disease (CAD), ischemic stroke (IS), and other cardiovascular events. 2–5 Whether NAFLD is independently related to ASCVD remains debatable. However, in recent years, there has been increasing epidemiologic, genetic, mechanistic, and observational evidence to support that NAFLD can directly or indirectly aggravate the pathogenesis of atherosclerosis and related clinical events, indicating that NAFLD could be an emerging independent risk factor and potential therapeutic target for ASCVD. Most recently, the American Heart Association released a scientific statement to highlight the clinical implication of treating and preventing NAFLD to reduce the risk of ASCVD. 5 This narrative review systematically summarizes the relationship between NAFLD and ASCVD by discussing the underlying pathophysiologic mechanisms linking NAFLD to atherosclerosis and exploring the prospect of novel treatment strategies for NAFLD that could also benefit the risk reduction of ASCVD.

Research Advances in Extrahepatic Diseases Associated with Nonalcoholic Fatty Liver Disease

[Research Advances in Diagnosis of Non-Alcoholic Fatty Liver Disease].

Recent Progress of Proteomics in Nonalcoholic Fatty Liver Disease*

LncRNA and circRNA in Patients with Non-Alcoholic Fatty Liver Disease: A Systematic Review

The Latest Research Progress of Non-alcoholic Fatty Liver Disease-related Hepatocellular Carcinoma

Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)

Research advances in non-alcoholic fatty liver disease: a review of current status and prospect

Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases

The regulatory role of metabolic organ-secreted factors in the nonalcoholic fatty liver disease and cardiovascular disease.

Progress in Non-invasive Diagnosis and Assessment of Non-alcoholic Fatty Liver Disease

Research advances in the impact of nonalcoholic fatty liver disease on cardiac structure and function

Recent Advances in Adipose Tissue Dysfunction and Its Role in the Pathogenesis of Non-Alcoholic Fatty Liver Disease

Non-alcoholic Fatty Liver Disease: the Problems We Are Facing.

Current status of research on nonalcoholic fatty liver disease in China

Non-alcoholic Steatohepatitis Pathogenesis, Diagnosis, and Treatment

Molecular mechanisms of metabolic disease-associated hepatic inflammation in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis

Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease

Nonalcoholic Fatty Liver Disease: Dyslipidemia, Risk for Cardiovascular Complications, and Treatment Strategy

Emerging targets and potential therapeutic agents in non-alcoholic fatty liver disease treatment

Emerging mechanisms of non-alcoholic steatohepatitis and novel drug therapies

Nonalcoholic Fatty Liver Disease as an Emerging Risk Factor and Potential Intervention Target for Atherosclerotic Cardiovascular Diseases